Lifesaving Cancer Drugs in India Cost 80 Times the Average Monthly Wage
Life-saving immunotherapy drugs for head and neck cancer remain far too expensive for most patients in India. A new analysis shows that even a six-month course of treatment can cost up to 80 times the average monthly income. Without major pricing changes, these modern therapies will stay out of reach for families already struggling with high medical bills.
Head and neck cancers are widespread in India, often linked to tobacco, areca nut, and alcohol use. Many patients receive a diagnosis only at advanced stages, forcing them to pay for treatment from personal savings. Immunotherapy drugs like Pembrolizumab and Nivolumab have shown survival benefits, but their costs are staggering.
In India, a six-month course of Pembrolizumab costs nearly 80 times the average monthly wage. Nivolumab is slightly cheaper but still exceeds 20 times the typical income for the same period. These prices mean that funding one patient's Pembrolizumab treatment could instead cover 18 to 22 patients using older, more affordable targeted therapies.
The core problem is not a lack of medical progress but pricing that ignores real-world earnings. With most healthcare spending coming directly from patients' pockets, high drug costs can push entire families into poverty. No large-scale study has compared these expenses across multiple countries, though similar affordability issues exist in the USA.
The financial burden of immunotherapy forces many Indian families to choose between treatment and financial ruin. Without reforms to lower drug prices, these therapies will remain inaccessible to those who need them most. The gap between medical innovation and affordability continues to widen, leaving patients with few realistic options.
